Edition:
United Kingdom

People: Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

24.67USD
18 Jul 2019
Change (% chg)

-- (--)
Prev Close
$24.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
241,911
52-wk High
$36.69
52-wk Low
$17.90

Hirsch, Andrew 

Mr. Andrew Hirsch is Independent Director of the Company. Mr. Hirsch is currently the Chief Financial Officer and Head of Corporate Development of Agios. Mr. Hirsch has served as Agios' Chief Financial Officer since September 2016 and as its Head of Corporate Development since March 2018. He has more than 22 years of experience in a range of strategic and operating roles in business, including over 17 years in the biotech industry, most recently having served as President and Chief Executive Officer of BIND Therapeutics, Inc., a biotechnology company ("BIND"), from March 2015 until August 2016. Prior to being named President and Chief Executive Officer at BIND, Mr. Hirsch held several other leadership positions at BIND, including Chief Operating Officer from February 2014 to March 2015, and Chief Financial Officer from July 2012 to March 2015. In May 2016, BIND filed a voluntary petition for bankruptcy under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court. Prior to joining BIND, Mr. Hirsch was chief financial officer at Avila Therapeutics, Inc., a biotechnology company, from June 2011 until its acquisition by Celgene Corporation, a public biopharmaceutical company, in March 2012. From 2002 to 2011, Mr. Hirsch held roles of increasing responsibility at Biogen, including vice president of Corporate Strategy and M&A and program executive for the Tecfidera development team. He holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania. We believe Mr. Hirsch's qualifications to sit on our Board include his strong business background and experience as an executive at biopharmaceutical companies.

Basic Compensation

Total Annual Compensation, USD 54,069
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 302,956
Fiscal Year Total, USD 357,025

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Mullen

612,362

Cynthia Collins

479,814

Eric Ek

--

Vickesh Myer

2,455,740

Charles Albright

2,387,900

Katrine Bosley

7,989,380
As Of  31 Dec 2018